Cowen analyst Yaron Werber raised the firm’s price target on FibroGen to $25 from $15 and keeps a Market Perform rating on the shares. The analyst said they have a catalyst-rich calendar ahead including data from Ph3 MDS, DMD, and IPF.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FGEN:
- FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
- FibroGen reports Q4 EPS (70c), consensus (94c)
- FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
- FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
- FibroGen to Present at SVB Securities Global Biopharma Conference
